By Dr Subotheni Thavaneswaran

Book Chapters

Lin FP; Tran M; Thavaneswaran S; Grady JP; Kansara M; Chan J; Ballinger ML; Simes J; Thomas DM, 2025, 'Automating Precision Oncology Literature Curation: A Decision Tree Approach Using Large Language Models', in , pp. 248 - 252, http://dx.doi.org/10.3233/SHTI250839

Journal articles

Kong BY; Lin FP-Y; Espinoza D; Aberoumand M; Thavaneswaran S; Meniawy T; Desai J; Harrup R; Nayagam SS; Charakidis M; Cuff K; Sebastian L; Lee CK; Wheeler P; Kansara M; Grady JP; Thomas DM; Ballinger ML; Simes J; Goldstein D, 2026, 'Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplifications: a molecular screening and therapeutics (MoST) program substudy', npj Precision Oncology, http://dx.doi.org/10.1038/s41698-026-01590-z

Kok PS; Chan B; Aberoumoud M; Zhang A; O’Byrne K; Thavaneswaran S; Lin F; Kansara M; Corpuz T; Wheeler P; Simes RJ; Thomas D; Lee CK, 2026, 'Phase II Trial of First-Line Durvalumab and Chemotherapy in Patients With Extra-Pulmonary Small Cell Carcinoma', Jto Clinical and Research Reports, 7, http://dx.doi.org/10.1016/j.jtocrr.2026.101014

Cote GM; Aberoumand M; Choy E; Sebastian L; Mazzola E; Grimison P; Merriam P; Ballinger M; Thavaneswaran S; Lin F; Grady JP; Millward M; Brown MP; Harrup R; Espinoza D; Demetri G; Littlefield BA; Simes RJ; George S; Thomas D, 2026, 'A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma', Clinical Cancer Research, 32, pp. 2206 - 2213, http://dx.doi.org/10.1158/1078-0432.CCR-25-3362

Lin FP; Thavaneswaran S; Grady JP; Napier CE; Kansara M; Sebastian L; Kee D; Desai J; Zaheed M; Chinchen S; Oakes SR; Blackburn J; Scott HS; Glover A; Fox SB; Goldstein D; Leo P; Amanuel B; Mersiades A; Millward M; Brown MP; Charakidis M; Pokorny AMJ; Craft P; Espinoza D; Grimison P; Harrup R; Joshua AM; O'byrne K; Lee CK; Cowley MJ; Ballinger ML; Simes J; Thomas DM, 2026, 'Genomic Therapy Matching in Rare and Refractory Cancers', JAMA Oncology, 12, pp. 458 - 467, http://dx.doi.org/10.1001/jamaoncol.2026.0127

Meng A; Yuile A; Sim HW; Thavaneswaran S; Noor H; Yeung J; Mehta A; Powell J; Zaman A, 2026, 'A Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid Tumours', Cancer Medicine, 15, http://dx.doi.org/10.1002/cam4.71888

Koh B; Thavaneswaran S; Lin F; Grady J; Maddula M; Haghighi KS; Kansara M; Huang ML; Ballinger ML; Simes J; Thomas DM; Goldstein D, 2026, 'Exceptional Response to Durvalumab and Tremelimumab in Pancreatic Acinar Cell Carcinoma With Ultramutated Phenotype Associated With a DNA Polymerase-ε Mutation', JCO Precision Oncology, 10, http://dx.doi.org/10.1200/PO-25-01003

Siu DHW; Lin FPY; Thomas DM; Thavaneswaran S; Espinoza D; Chinchen S; Ballinger ML; Simes RJ; Lee CK, 2026, 'Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program', Future Oncology, 22, pp. 1965 - 1974, http://dx.doi.org/10.1080/14796694.2026.2688570

Southi N; Sim H-W; Grady J; Ballinger M; Thomas D; Thavaneswaran S, 2026, '145P Characterising homologous recombination deficiencies in gliomas', ESMO Open, 11, pp. 106288 - 106288, http://dx.doi.org/10.1016/j.esmoop.2026.106288

Thavaneswaran S; Lin F; Espinoza D; Grady J; Kok PS; Chinchen S; Pavlakis N; Andelkovic V; Charakidis M; Craft P; Brown M; Desai J; Lau P; Kansara M; Simes J; Thomas D, 2025, 'A signal-seeking phase 2 study of tremelimumab in advanced cancers with high tumour mutational burden', Npj Precision Oncology, 9, http://dx.doi.org/10.1038/s41698-025-01156-5

Patil T; Lin JJ; Cheema PK; Carrizosa DR; Burkard ME; Elamin YY; Desai J; Patel JD; Nagasaka M; Reckamp KL; Waqar SN; Bauman JR; Schram AM; Gadgeel SM; Ma PC; Konduri K; Nguyen D; Misleh J; Bleeker J; Weiss M; Thavaneswaran S; Haura EB; Deegan M; Kaufman J; Srivastava J; Jansen VM; Liu SV, 2025, 'CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions', JCO Precision Oncology, 9, http://dx.doi.org/10.1200/PO-25-00221

Yuile A; Satgunaseelan L; Alexander KL; Thavaneswaran S; Sim HW; Krasovitsky M; Kong BY; Miller S; Buckland ME; Lee M; Wei G; Kastelan M; Wong M; Wilson I; Bayly A; Varikatt W; Lwin Z; Turner C; Back MF; Pavlakis N; Wei JQ; Hudson A; Chan DL; Wheeler HR; Lee A, 2025, 'Clinical outcomes and management of CDKN2A/B homozygously deleted IDH-mutant astrocytomas—a cohort study and patterns of care survey', Neuro Oncology Practice, 12, pp. 787 - 796, http://dx.doi.org/10.1093/nop/npaf045

Thavaneswaran S; Sim HW; Grady J; Espinoza D; Huang ML; Lin F; McGrath M; Desai J; Charakidis M; Brown M; Kansara M; Simes J; Thomas D, 2025, 'A phase II trial of larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA overexpression identified by comprehensive genomic profiling', Oncologist, 30, http://dx.doi.org/10.1093/oncolo/oyae339

Maddula M; McNamee N; Gan HK; Satgunaseelan L; Koh ES; Han CH; Thavaneswaran S, 2025, 'Contemporary Patterns of Care for Low-Grade Glioma in Australia and New Zealand', Current Oncology, 32, http://dx.doi.org/10.3390/curroncol32030183

McParland K; Koh ES; Kong B; Sim HW; Thavaneswaran S; Yip S; Barnes EH; Ballinger ML; Thomas DM; De Abreu Lourenco R; Simes J; Sebastian L; Wheeler PJ; Spyridopoulos D; Hawkins C; Pitz M; O'Callaghan C; Gan HK, 2025, 'Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre, open-label, multiarm, biomarker-directed, signal-seeking, umbrella, clinical trial for recurrent IDH mutant, grade 2/3 glioma', BMJ Open, 15, http://dx.doi.org/10.1136/BMJOPEN-2024-087922

Novis E; Glover A; Grady JP; Silvestri A; Thavaneswaran S; Lin F; Ballinger ML; Thomas DM, 2025, 'Oncogenic mutations in the TP53 and PI-3 kinase/AKT pathway are independent predictors of survival for advanced thyroid cancer: Analysis from the Molecular Screening and Therapeutics (MoST) program', Surgery United States, 177, http://dx.doi.org/10.1016/j.surg.2024.05.058

Kansara M; Thavaneswaran S; Lin FP; Kok P-S; Grady J; Thomas H; Corpuz T; Mundra P; Lu J; Ballinger M; Desai J; Harrup RA; Craft P; Charakidis M; O'Byrne KJ; Selva-Nayagam S; Millward M; Grimison P; Simes J; Thomas D, 2025, '1544P A phase II trial of palbociclib and avelumab in advanced solid tumours with CDK4/6 pathway alterations', Annals of Oncology, 36, pp. s922 - s923, http://dx.doi.org/10.1016/j.annonc.2025.08.2175

Kok PS; Chan B; Zhang A; O'Byrne K; Aberoumoud M; Thavaneswaran S; Lin FP; Kansara M; Corpuz T; Wheeler P; Simes J; Thomas DM; Lee CK, 2025, '181P Phase II trial of first-line durvalumab and chemotherapy in patients with extra-pulmonary small cell carcinoma', Annals of Oncology, 36, pp. s1816, http://dx.doi.org/10.1016/j.annonc.2025.10.1018

Kansara M; Lin FP; Thavaneswaran S; Huang ML; Tran M; Corpuz T; Lu J; Espinoza D; Chinchen S; Ballinger M; Grimison P; Andelkovic V; Dow EG; Desai J; Simes J; Thomas D, 2025, '2715P Phase II trial of tildrakizumab in treatment-refractory bone and soft tissue sarcomas', Annals of Oncology, 36, pp. s1447, http://dx.doi.org/10.1016/j.annonc.2025.08.3325

Gaughran G; Body A; Thavaneswaran S; Bellinger M; Harris SJ; Davies AG; Huang ML; Kee D; Thomas D, 2025, '82P Y220C, a rare but druggable TP53 mutation: A molecular landscape in an Australian context', ESMO Open, 10, pp. 105432 - 105432, http://dx.doi.org/10.1016/j.esmoop.2025.105432

Lin FP; Itchins M; Chinchen S; Thavaneswaran S; Mersiades A; Aberoumand M; Nagrial A; Xu W; Takhar HS; Harrup RA; Desai J; Cummins M; Espinoza D; Kansara M; Yip S; Lee CK; Simes J; Solomon BJ; Pavlakis N; Thomas D, 2025, '996P Phase II trial of alectinib in ALK-altered solid tumours and NSCLC with negative standard care testing: Australian molecular screening and therapeutics (MoST) substudy 14', Annals of Oncology, 36, pp. s651, http://dx.doi.org/10.1016/j.annonc.2025.08.1565

Lin FP-Y; Goldstein D; Grady JP; Napier C; Thavaneswaran S; Pitiyarachchi O; Kansara M; Chantrill LA; Sjoquist K; Thornton K; Raina A; Magenau A; Simes J; Ballinger ML; Sharbeen G; Timpson P; Pajic M; Phillips P; Thomas DM, 2025, 'Genomic and outcome analysis of recurrent versus de novo metastatic pancreatic ductal adenocarcinoma (PDAC) receiving systemic therapy: Results from the Australian MoST and CaSP screening programs.', Journal of Clinical Oncology, 43, pp. 4120 - 4120, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.4120

Gaughran G; Zaheed M; Harris SJ; Napier C; Yap M; Bellinger M; Grady J; Kee D; Caillet V; Davies A; Thavaneswaran S; Thomas DM, 2025, 'HIF2α pathway aberrations across tumour types: A rare but actionable entity with high germline conversion', ANNALS OF ONCOLOGY, 36, http://dx.doi.org/10.1016/j.annonc.2025.10.1192

Lin FP-Y; Huang ML; Grady JP; Thavaneswaran S; Kansara M; Napier C; Ballinger ML; Simes J; Thomas DM, 2025, 'Machine learning–based classification of cancer types using genomic profiling data from the Australian Molecular Screening and Therapeutics (MoST) program.', Journal of Clinical Oncology, 43, pp. e13683 - e13683, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.e13683

Pavlakis N; Lee CK; Ballinger ML; Brown CSB; Grady JP; Lin F; Thavaneswaran S; Mersiades AJ; Di-Xin Zhou D; Lee J; John T; Napier CE; Cummins MM; Collignon E; Sebastian L; Turnbull OMH; Simes J; Thomas DM; Solomon BJ, 2025, 'P2.06.61 ASPiRATION. Australian Nationwide Cohort Study to Assess Impact of Comprehensive Genomic Profiling in Metastatic Lung Cancer', Journal of Thoracic Oncology, 20, pp. S318 - S319, http://dx.doi.org/10.1016/j.jtho.2025.09.595

Gaughran G; Mamrot J; Fitzgerald S; Kee D; Napier C; Harris SJ; Thavaneswaran S; Grady J; Davies A; Bellinger M; Thomas DM, 2025, 'Real-world experience of liquid biopsy (LBx) vs tissue-based comprehensive genomic profiling (tCGP)', ANNALS OF ONCOLOGY, 36, http://dx.doi.org/10.1016/j.annonc.2025.10.1211

Thavaneswaran S; Lin F; Grady JP; Espinoza D; Huang ML; Chinchen S; Sebastian L; Kansara M; Mersiades T; Lee CK; Desai J; Grimison P; Brown M; Millward M; Harrup R; O’Byrne K; Nagrial A; Craft P; Simes J; Joshua AM; Thomas DM, 2024, 'A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation', Npj Precision Oncology, 8, http://dx.doi.org/10.1038/s41698-024-00698-4

Deng F; Li Y; Yang B; Sang R; Deng W; Kansara M; Lin F; Thavaneswaran S; Thomas DM; Goldys EM, 2024, 'Topological barrier to Cas12a activation by circular DNA nanostructures facilitates autocatalysis and transforms DNA/RNA sensing', Nature Communications, 15, pp. 1818, http://dx.doi.org/10.1038/s41467-024-46001-8

McNamee N; Lin F; Sim H-W; Napier C; Thomas D; Simes J; Thavaneswaran S, 2023, 'PATH-25. EXPLORING THE PROGNOSTIC IMPLICATIONS OF MOLECULAR ALTERATIONS IN ASTROCYTOMAS USING COMPREHENSIVE GENOMIC PROFILING (CGP)', Neuro-Oncology, 25, pp. v173 - v173, http://dx.doi.org/10.1093/neuonc/noad179.0655

Zeverijn LJ; Looze EJ; Thavaneswaran S; van Berge Henegouwen JM; Simes RJ; Hoes LR; Sjoquist KM; van der Wijngaart H; Sebastian L; Geurts BS; Lee CK; de Wit GF; Espinoza D; Roepman P; Lin FP; Jansen AML; de Leng WWJ; van der Noort V; Leek LVM; de Vos FYFL; van Herpen CML; Gelderblom H; Verheul HMW; Thomas DM; Voest EE, 2023, 'Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials', International Journal of Cancer, 153, pp. 1413 - 1422, http://dx.doi.org/10.1002/ijc.34649

Thavaneswaran S; Kansara M; Lin F; Espinoza D; Grady JP; Lee CK; Ballinger ML; Sebastian L; Corpuz T; Qiu MR; Mundra P; Bailey CG; Schmitz U; Simes J; Joshua AM; Thomas DM, 2023, 'A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations', British Journal of Cancer, 129, pp. 475 - 485, http://dx.doi.org/10.1038/s41416-023-02311-0

Zeverijn LJ; Looze E; Thavaneswaran S; van Berge Henegouwen JM; Simes J; Hoes LR; Geurts B; Sebastian L; Roepman P; Lin FP-Y; Jansen AML; de Leng WWJ; van der Noort V; Leek LVM; De Vos FYFL; Verheul HMW; Gelderblom H; Thomas DM; Voest EE; Sjoquist KM, 2023, 'Clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.', Journal of Clinical Oncology, 41, pp. 3101 - 3101, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3101

Kansara M; Lin FP-Y; Thavaneswaran S; Napier CE; Grady JP; Ballinger ML; Simes J; Thomas DM, 2023, 'Genomic alterations associated with response to immune checkpoint inhibitors in rare cancers: A biomarker exploration study from the Australian Molecular Screening and Therapeutics (MoST) Program.', Journal of Clinical Oncology, 41, pp. 2594 - 2594, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.2594

Thavaneswaran S; Lin FP-Y; Napier CE; Grady JP; Ballinger ML; Kansara M; Grimison PS; Pavlakis N; Wong MK; Sjoquist KM; Goldstein D; Chantrill LA; Simes J; Thomas DM, 2023, 'Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program.', Journal of Clinical Oncology, 41, pp. 4093 - 4093, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.4093

Lin FP-Y; Thavaneswaran S; Napier CE; Grady JP; Kansara M; Sebastian L; Kee D; Zaheed M; Millward M; Brown MP; Charakidis M; Craft PS; Grimison PS; Harrup RA; O'Byrne KJ; Desai J; Lee CK; Ballinger ML; Simes J; Thomas DM, 2023, 'Genomic therapy matching in rare and refractory cancers: Updated results from a retrospective cohort study in the Molecular Screening and Therapeutic (MoST) program.', Journal of Clinical Oncology, 41, pp. 1540 - 1540, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.1540

Kee D; Lin FP-Y; Thavaneswaran S; Napier CE; Harrison ML; Beale PJ; Lynch J; Davis AJ; Ananda S; Lombard JM; Friedlander M; Kansara M; Sebastian L; Lee CK; Ballinger ML; Simes J; Thomas DM, 2023, 'Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program.', Journal of Clinical Oncology, 41, pp. 5526 - 5526, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5526

Thavaneswaran S; Mersiades A; Lin FP-Y; Espinoza D; Grady JP; Lee CK; Desai J; Brown MP; Grimison PS; O'Byrne KJ; Harrup RA; Nagrial A; Sebastian L; Chinchen S; Kansara M; Craft PS; Millward M; Simes J; Joshua AM; Thomas DM, 2023, 'Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.', Journal of Clinical Oncology, 41, pp. 3127 - 3127, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3127

Kansara M; Bhardwaj N; Thavaneswaran S; Xu C; Lee JK; Chang LB; Madison RW; Lin F; Hsu E; Patel VK; Aleshin A; Oxnard GR; Simes J; Nimeiri H; Thomas DM, 2023, 'Early circulating tumor DNA dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumab', Molecular Oncology, 17, pp. 298 - 311, http://dx.doi.org/10.1002/1878-0261.13349

Yuile A; Satgunaseelan L; Alexander KL; Thavaneswaran S; Krasovitsky M; Buckland M; Lee M; Wei G; Kastelan M; Wong M; Wilson I; Bayly A; Varikat W; Sim H-W; Kong B; Lwin Z; Turner C; Back M; Miller S; Lee A; Wheeler H, 2022, 'CSIG-13. CLINICAL IMPACT OF CDKN2A/B DELETIONS IN IDH-MUTANT ASTROCYTOMAS', Neuro-Oncology, 24, pp. vii41 - vii41, http://dx.doi.org/10.1093/neuonc/noac209.162

Woodford R; Prather L; Helfer C; Davey L; Penas-Prado M; Armstrong T; Tucker K; Aldape K; Gilbert M; Clark C; Thavaneswaran S; Wang D; Mandel J; Kasherman L, 2022, 'Malignant melanocytic schwannian tumor and leptomeningeal disease: A case series with a focus on management', Journal of the Neurological Sciences, 438, http://dx.doi.org/10.1016/j.jns.2022.120291

Thavaneswaran S; Chan WY; Asghari R; Grady JP; Deegan M; Jansen VM; Thomas DM, 2022, 'Clinical Response to Seribantumab, an Anti–Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an NRG1 Fusion', JCO Precision Oncology, 6, pp. e2200263, http://dx.doi.org/10.1200/po.22.00263

Lin FP; Thavaneswaran S; Grady JP; Ballinger M; Kansara M; Oakes SR; Desai J; Lee CK; Simes J; Thomas DM, 2021, 'Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology', Npj Precision Oncology, 5, pp. 58, http://dx.doi.org/10.1038/s41698-021-00194-z

Siu HWD; Tebbutt N; Chantrill L; Karapetis C; Steer C; Wilson K; Espinoza D; Bailey L; Yip S; Cuff J; Pavlakis N; Thavaneswaran S; Briscoe K; Srivastav R; Shannon J; Segelov E; Tie J; Caird S; Francesconi A; Price T; Wuttke M; Ladwa R; Sjoquist K; Burge M, 2021, 'MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)', BMC Cancer, 21, http://dx.doi.org/10.1186/s12885-021-08644-4

Thavaneswaran S; Ballinger M; Butow P; Meiser B; Goldstein D; Lin F; Napier C; Thomas D; Best M, 2021, 'The experiences and needs of australian medical oncologists in integrating comprehensive genomic profiling into clinical care: A nation-wide survey', Oncotarget, 12, pp. 2169 - 2176, http://dx.doi.org/10.18632/ONCOTARGET.28076

Joshua AM; Prawira A; Thavaneswaran S; Cosman R; Lee CK; Sjoquist KM; Simes J; Thomas DM; Espinoza D; Sebastian L; Ballinger ML; Hague W; Chinchen S; Collignon E; Kansara M; Palacios T; Grady J; Barker H; Thornton K, 2020, 'A signal-seeking trial of olaparib and durvalumab in homologous repair-deficient tumors: A sub-study of the cancer molecular screening and therapeutics (MoST) program.', Journal of Clinical Oncology, 38, pp. 3073 - 3073, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3073

Thavaneswaran S; Rath E; Tucker K; Joshua AM; Hess D; Pinese M; Ballinger ML; Thomas DM, 2019, 'Author Correction: Therapeutic implications of germline genetic findings in cancer (Nature Reviews Clinical Oncology, (2019), 16, 6, (386-396), 10.1038/s41571-019-0179-3)', Nature Reviews Clinical Oncology, 16, pp. 397, http://dx.doi.org/10.1038/s41571-019-0212-6

Thavaneswaran S; Rath E; Tucker K; Joshua AM; Hess D; Pinese M; Ballinger ML; Thomas DM, 2019, 'Therapeutic implications of germline genetic findings in cancer', Nature Reviews Clinical Oncology, 16, pp. 386 - 396, http://dx.doi.org/10.1038/s41571-019-0179-3

Thavaneswaran S; Napier C; Goldstein D; Meiser B; Butow P; Thomas DM; Ballinger ML; Best M, 2019, 'Medical oncologists’ experience with returning molecular tumor profiling to patients.', Journal of Clinical Oncology, 37, pp. 10521 - 10521, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.10521

Shapiro JD; Thavaneswaran S; Underhill CR; Robledo KP; Karapetis CS; Day FL; Nott LM; Jefford M; Chantrill LA; Pavlakis N; Tebbutt NC; Price TJ; Khasraw M; Van Hazel GA; Waring PM; Tejpar S; Simes J; Gebski VJ; Desai J; Segelov E, 2018, 'Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study', Clinical Colorectal Cancer, 17, pp. 313 - 319, http://dx.doi.org/10.1016/j.clcc.2018.06.002

Thavaneswaran S; Sebastian L; Ballinger M; Best M; Hess D; Lee CK; Sjoquist KM; Hague WE; Butow PN; Simes RJ; Thomas D, 2018, 'Cancer Molecular Screening and Therapeutics (MoST): A framework for multiple, parallel signal-seeking studies of targeted therapies for rare and neglected cancers', Medical Journal of Australia, 209, pp. 354 - 354.e6, http://dx.doi.org/10.5694/MJA18.00227

Back to profile page